Literature DB >> 22560915

Anti-inflammatory effects of ivabradine in patients with acute coronary syndrome: a pilot study.

Alberto Dominguez-Rodriguez, Luciano Consuegra-Sanchez, Gabriela Blanco-Palacios, Pedro Abreu-Gonzalez, Alejandro Sanchez-Grande, Francisco Bosa-Ojeda, Juan Carlos Kaski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22560915     DOI： 10.1016/j.ijcard.2012.04.076

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  8 in total

Review 1.  The Risk of Atrial Fibrillation With Ivabradine Treatment: A Meta-analysis With Trial Sequential Analysis of More Than 40000 Patients.

Authors:  İbrahim Halil Tanboğa; Selim Topçu; Enbiya Aksakal; Oktay Gulcu; Emrah Aksakal; Uğur Aksu; Vecih Oduncu; Fatih Rıfat Ulusoy; Serdar Sevimli; Cihangir Kaymaz
Journal:  Clin Cardiol       Date:  2016-08-11       Impact factor: 2.882

2.  Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials.

Authors:  Ruairidh I R Martin; Oksana Pogoryelova; Mauro Santibáñez Koref; John P Bourke; M Dawn Teare; Bernard D Keavney
Journal:  Heart       Date:  2014-06-20       Impact factor: 5.994

3.  The Protective Effects of Ivabradine in Preventing Progression from Viral Myocarditis to Dilated Cardiomyopathy.

Authors:  Li Yue-Chun; Chen Guang-Yi; Ge Li-Sha; Xing Chao; Tian Xinqiao; Lin Cong; Dai Xiao-Ya; Yang Xiangjun
Journal:  Front Pharmacol       Date:  2016-11-01       Impact factor: 5.810

4.  Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure.

Authors:  Ilonka Rohm; Daniel Kretzschmar; Rudin Pistulli; Marcus Franz; P Christian Schulze; Christian Stumpf; Atilla Yilmaz
Journal:  J Immunol Res       Date:  2016-10-16       Impact factor: 4.818

5.  Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.

Authors:  Peter Jirak; Dzeneta Fejzic; Vera Paar; Bernhard Wernly; Rudin Pistulli; Ilonka Rohm; Christian Jung; Uta C Hoppe; P Christian Schulze; Michael Lichtenauer; Atilla Yilmaz; Daniel Kretzschmar
Journal:  Acta Pharmacol Sin       Date:  2017-12-14       Impact factor: 6.150

6.  The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument.

Authors:  Hayder M Al-Kuraishy; Hajer K Issa; Ali I Al-Gareeb; Maisra M El-Bouseary; Amal Youssef; Ahmed Shaban Abdelaziz; Hesham Ahmed Khalifa; Gaber El-Saber Batiha
Journal:  Inflammopharmacology       Date:  2022-10-11       Impact factor: 5.093

Review 7.  Immunopharmacology of Post-Myocardial Infarction and Heart Failure Medications.

Authors:  Mona Panahi; Nimai Vadgama; Mathun Kuganesan; Fu Siong Ng; Susanne Sattler
Journal:  J Clin Med       Date:  2018-10-31       Impact factor: 4.241

8.  Effects of adding ivabradine to usual care in patients with angina pectoris: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis.

Authors:  Mathias Maagaard; Emil Eik Nielsen; Naqash Javaid Sethi; Liang Ning; Si-Hong Yang; Christian Gluud; Janus Christian Jakobsen
Journal:  Open Heart       Date:  2020-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.